HLA Class I and II Diversity Contributes to the Etiologic
Heterogeneity of Non-Hodgkin Lymphoma Subtypes

J 2018

HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes

WANG, S.S., M. CARRINGTON, S.I. BERNDT, S.L. SLAGER, P.M. BRACCI et. al.

Basic information

Original name

HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes

Authors

WANG, S.S. (840 United States of America), M. CARRINGTON (840 United States of America), S.I. BERNDT (840 United States of America), S.L. SLAGER (840 United States of America), P.M. BRACCI (840 United States of America), J. VOUTSINAS (840 United States of America), J.R. CERHAN (840 United States of America), K.E. SMEDBY (840 United States of America), H. HJALGRIM (208 Denmark), J. VIJAI (840 United States of America), L.M. MORTON (840 United States of America), R. VERMEULEN (528 Netherlands), O. PALTIEL (376 Israel), C.M. VAJDIC (36 Australia), M.S. LINET (840 United States of America), A. NIETERS (276 Germany), S. de SANJOSE (724 Spain), W. COZEN (840 United States of America), E.E. BROWN (840 United States of America), J. TURNER (36 Australia), J.J. SPINELLI (124 Canada), T.Z. ZHENG (840 United States of America), B.M. BIRMANN (840 United States of America), C.R. FLOWERS (840 United States of America), N. BECKER (276 Germany), E.A. HOLLY (840 United States of America), E. KANE (826 United Kingdom of Great Britain and Northern Ireland), D. WEISENBURGER (840 United States of America), M. MAYNADIE (250 France), P. COCCO (380 Italy), D. ALBANES (840 United States of America), S.J. WEINSTEIN (840 United States of America), L.R. TERAS (840 United States of America), W.R. DIVER (840 United States of America), S.J. LAX (826 United Kingdom of Great Britain and Northern Ireland), R.C. TRAVIS (826 United Kingdom of Great Britain and Northern Ireland), R. KAAKS (276 Germany), E. RIBOLI (826 United Kingdom of Great Britain and Northern Ireland), Y. BENAVENTE (826 United Kingdom of Great Britain and Northern Ireland), P. BRENNAN (724 Spain), J. MCKAY (250 France), M.H. DELFAU-LARUE (250 France), B.K. LINK (840 United States of America), C. MAGNANI (380 Italy), M.G. ENNAS (380 Italy), G. LATTE (380 Italy), A.L. FELDMAN (840 United States of America), N.W. DOO (36 Australia), G.G. GILES (36 Australia), M.C. SOUTHEY (36 Australia), R.L. MILNE (36 Australia), K. OFFIT (208 Denmark), J. MUSINSKY (208 Denmark), A.A. ARSLAN (840 United States of America), M.P. PURDUE (840 United States of America), H.O. ADAMI (752 Sweden), M. MELBYE (840 United States of America), B. GLIMELIUS (752 Sweden), L. CONDE (826 United Kingdom of Great Britain and Northern Ireland), N.J. CAMP (840 United States of America), M. GLENN (840 United States of America), K. CURTIN (840 United States of America), J. CLAVEL (250 France), A. MONNEREAU (250 France), D.G. COX (826 United Kingdom of Great Britain and Northern Ireland), H. GHESQUIERES (250 France), G. SALLES (250 France), P. BOFETTA (840 United States of America), Lenka FORETOVÁ (203 Czech Republic, belonging to the institution), A. STAINES (826 United Kingdom of Great Britain and Northern Ireland), S. DAVIS (840 United States of America), R.K. SEVERSON (840 United States of America), Q. LAN (840 United States of America), A. BROOKS-WILSON (124 Canada), M.T. SMITH (840 United States of America), E. ROMAN (826 United Kingdom of Great Britain and Northern Ireland), A. KRICKER (36 Australia), Y.W. ZHANG (840 United States of America), P. KRAFT (840 United States of America), S.J. CHANOCK (840 United States of America), N. ROTHMAN (840 United States of America), P. HARTGE (840 United States of America) and C.F. SKIBOLA (840 United States of America)

Edition

Cancer Research, PHILADELPHIA, AMER ASSOC CANCER RESEARCH, 2018, 0008-5472

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 8.378

RIV identification code

RIV/00216224:14110/18:00106857

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1158/0008-5472.CAN-17-2900

UT WoS

000439199100028

Keywords in English

leukocyte antigen

Abstract

V originále

A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of "heterozygote advantage" regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL = 1.31, 95% CI = 1.06-1.60; OR MZL = 1.45, 95% CI = 1.12-1.89) and class II HLA-DRB1 locus (OR DLBCL = 2.10, 95% CI = 1.24-3.55; OR MZL = 2.10, 95% CI = 0.99-4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (P trend < 0.0001, FDR = 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes. Significance: HLA gene diversity reduces risk for non-Hodgkin lymphoma. (C) 2018 AACR.

Citovat

WANG, S.S., M. CARRINGTON, S.I. BERNDT, S.L. SLAGER, P.M. BRACCI, J. VOUTSINAS, J.R. CERHAN, K.E. SMEDBY, H. HJALGRIM, J. VIJAI, L.M. MORTON, R. VERMEULEN, O. PALTIEL, C.M. VAJDIC, M.S. LINET, A. NIETERS, S. de SANJOSE, W. COZEN, E.E. BROWN, J. TURNER, J.J. SPINELLI, T.Z. ZHENG, B.M. BIRMANN, C.R. FLOWERS, N. BECKER, E.A. HOLLY, E. KANE, D. WEISENBURGER, M. MAYNADIE, P. COCCO, D. ALBANES, S.J. WEINSTEIN, L.R. TERAS, W.R. DIVER, S.J. LAX, R.C. TRAVIS, R. KAAKS, E. RIBOLI, Y. BENAVENTE, P. BRENNAN, J. MCKAY, M.H. DELFAU-LARUE, B.K. LINK, C. MAGNANI, M.G. ENNAS, G. LATTE, A.L. FELDMAN, N.W. DOO, G.G. GILES, M.C. SOUTHEY, R.L. MILNE, K. OFFIT, J. MUSINSKY, A.A. ARSLAN, M.P. PURDUE, H.O. ADAMI, M. MELBYE, B. GLIMELIUS, L. CONDE, N.J. CAMP, M. GLENN, K. CURTIN, J. CLAVEL, A. MONNEREAU, D.G. COX, H. GHESQUIERES, G. SALLES, P. BOFETTA, Lenka FORETOVÁ, A. STAINES, S. DAVIS, R.K. SEVERSON, Q. LAN, A. BROOKS-WILSON, M.T. SMITH, E. ROMAN, A. KRICKER, Y.W. ZHANG, P. KRAFT, S.J. CHANOCK, N. ROTHMAN, P. HARTGE and C.F. SKIBOLA. HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Research. PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2018, vol. 78, No 14, p. 4086-4096. ISSN 0008-5472. Available from: https://dx.doi.org/10.1158/0008-5472.CAN-17-2900.

@article{1526399,
   author = {Wang, S.S. and Carrington, M. and Berndt, S.I. and Slager, S.L. and Bracci, P.M. and Voutsinas, J. and Cerhan, J.R. and Smedby, K.E. and Hjalgrim, H. and Vijai, J. and Morton, L.M. and Vermeulen, R. and Paltiel, O. and Vajdic, C.M. and Linet, M.S. and Nieters, A. and Sanjose, S. de and Cozen, W. and Brown, E.E. and Turner, J. and Spinelli, J.J. and Zheng, T.Z. and Birmann, B.M. and Flowers, C.R. and Becker, N. and Holly, E.A. and Kane, E. and Weisenburger, D. and Maynadie, M. and Cocco, P. and Albanes, D. and Weinstein, S.J. and Teras, L.R. and Diver, W.R. and Lax, S.J. and Travis, R.C. and Kaaks, R. and Riboli, E. and Benavente, Y. and Brennan, P. and McKay, J. and DelfauandLarue, M.H. and Link, B.K. and Magnani, C. and Ennas, M.G. and Latte, G. and Feldman, A.L. and Doo, N.W. and Giles, G.G. and Southey, M.C. and Milne, R.L. and Offit, K. and Musinsky, J. and Arslan, A.A. and Purdue, M.P. and Adami, H.O. and Melbye, M. and Glimelius, B. and Conde, L. and Camp, N.J. and Glenn, M. and Curtin, K. and Clavel, J. and Monnereau, A. and Cox, D.G. and Ghesquieres, H. and Salles, G. and Bofetta, P. and Foretová, Lenka and Staines, A. and Davis, S. and Severson, R.K. and Lan, Q. and BrooksandWilson, A. and Smith, M.T. and Roman, E. and Kricker, A. and Zhang, Y.W. and Kraft, P. and Chanock, S.J. and Rothman, N. and Hartge, P. and Skibola, C.F.},
   article_location = {PHILADELPHIA},
   article_number = {14},
   doi = {http://dx.doi.org/10.1158/0008-5472.CAN-17-2900},
   keywords = {leukocyte antigen},
   language = {eng},
   issn = {0008-5472},
   journal = {Cancer Research},
   title = {HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes},
   url = {http://dx.doi.org/10.1158/0008-5472.CAN-17-2900},
   volume = {78},
   year = {2018}
}

TY  - JOUR
ID  - 1526399
AU  - Wang, S.S. - Carrington, M. - Berndt, S.I. - Slager, S.L. - Bracci, P.M. - Voutsinas, J. - Cerhan, J.R. - Smedby, K.E. - Hjalgrim, H. - Vijai, J. - Morton, L.M. - Vermeulen, R. - Paltiel, O. - Vajdic, C.M. - Linet, M.S. - Nieters, A. - Sanjose, S. de - Cozen, W. - Brown, E.E. - Turner, J. - Spinelli, J.J. - Zheng, T.Z. - Birmann, B.M. - Flowers, C.R. - Becker, N. - Holly, E.A. - Kane, E. - Weisenburger, D. - Maynadie, M. - Cocco, P. - Albanes, D. - Weinstein, S.J. - Teras, L.R. - Diver, W.R. - Lax, S.J. - Travis, R.C. - Kaaks, R. - Riboli, E. - Benavente, Y. - Brennan, P. - McKay, J. - Delfau-Larue, M.H. - Link, B.K. - Magnani, C. - Ennas, M.G. - Latte, G. - Feldman, A.L. - Doo, N.W. - Giles, G.G. - Southey, M.C. - Milne, R.L. - Offit, K. - Musinsky, J. - Arslan, A.A. - Purdue, M.P. - Adami, H.O. - Melbye, M. - Glimelius, B. - Conde, L. - Camp, N.J. - Glenn, M. - Curtin, K. - Clavel, J. - Monnereau, A. - Cox, D.G. - Ghesquieres, H. - Salles, G. - Bofetta, P. - Foretová, Lenka - Staines, A. - Davis, S. - Severson, R.K. - Lan, Q. - Brooks-Wilson, A. - Smith, M.T. - Roman, E. - Kricker, A. - Zhang, Y.W. - Kraft, P. - Chanock, S.J. - Rothman, N. - Hartge, P. - Skibola, C.F.
PY  - 2018
TI  - HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes
JF  - Cancer Research
VL  - 78
IS  - 14
SP  - 4086-4096
EP  - 4086-4096
PB  - AMER ASSOC CANCER RESEARCH
SN  - 00085472
KW  - leukocyte antigen
UR  - http://dx.doi.org/10.1158/0008-5472.CAN-17-2900
N2  - A growing number of loci within the human leukocyte antigen (HLA) region have been implicated in non-Hodgkin lymphoma (NHL) etiology. Here, we test a complementary hypothesis of "heterozygote advantage" regarding the role of HLA and NHL, whereby HLA diversity is beneficial and homozygous HLA loci are associated with increased disease risk. HLA alleles at class I and II loci were imputed from genome-wide association studies (GWAS) using SNP2HLA for 3,617 diffuse large B-cell lymphomas (DLBCL), 2,686 follicular lymphomas (FL), 2,878 chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLL), 741 marginal zone lymphomas (MZL), and 8,753 controls of European descent. Both DLBCL and MZL risk were elevated with homozygosity at class I HLA-B and -C loci (OR DLBCL = 1.31, 95% CI = 1.06-1.60; OR MZL = 1.45, 95% CI = 1.12-1.89) and class II HLA-DRB1 locus (OR DLBCL = 2.10, 95% CI = 1.24-3.55; OR MZL = 2.10, 95% CI = 0.99-4.45). Increased FL risk was observed with the overall increase in number of homozygous HLA class II loci (P trend < 0.0001, FDR = 0.0005). These results support a role for HLA zygosity in NHL etiology and suggests that distinct immune pathways may underly the etiology of the different NHL subtypes. Significance: HLA gene diversity reduces risk for non-Hodgkin lymphoma. (C) 2018 AACR.
ER  -

WANG, S.S., M. CARRINGTON, S.I. BERNDT, S.L. SLAGER, P.M. BRACCI, J. VOUTSINAS, J.R. CERHAN, K.E. SMEDBY, H. HJALGRIM, J. VIJAI, L.M. MORTON, R. VERMEULEN, O. PALTIEL, C.M. VAJDIC, M.S. LINET, A. NIETERS, S. de SANJOSE, W. COZEN, E.E. BROWN, J. TURNER, J.J. SPINELLI, T.Z. ZHENG, B.M. BIRMANN, C.R. FLOWERS, N. BECKER, E.A. HOLLY, E. KANE, D. WEISENBURGER, M. MAYNADIE, P. COCCO, D. ALBANES, S.J. WEINSTEIN, L.R. TERAS, W.R. DIVER, S.J. LAX, R.C. TRAVIS, R. KAAKS, E. RIBOLI, Y. BENAVENTE, P. BRENNAN, J. MCKAY, M.H. DELFAU-LARUE, B.K. LINK, C. MAGNANI, M.G. ENNAS, G. LATTE, A.L. FELDMAN, N.W. DOO, G.G. GILES, M.C. SOUTHEY, R.L. MILNE, K. OFFIT, J. MUSINSKY, A.A. ARSLAN, M.P. PURDUE, H.O. ADAMI, M. MELBYE, B. GLIMELIUS, L. CONDE, N.J. CAMP, M. GLENN, K. CURTIN, J. CLAVEL, A. MONNEREAU, D.G. COX, H. GHESQUIERES, G. SALLES, P. BOFETTA, Lenka FORETOVÁ, A. STAINES, S. DAVIS, R.K. SEVERSON, Q. LAN, A. BROOKS-WILSON, M.T. SMITH, E. ROMAN, A. KRICKER, Y.W. ZHANG, P. KRAFT, S.J. CHANOCK, N. ROTHMAN, P. HARTGE and C.F. SKIBOLA. HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. \textit{Cancer Research}. PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2018, vol.~78, No~14, p.~4086-4096. ISSN~0008-5472. Available from: https://dx.doi.org/10.1158/0008-5472.CAN-17-2900.

Detailed Information on Publication Record